Takeda Pharmaceutical (TAK) Income from Continuing Operations (2017 - 2026)

Takeda Pharmaceutical has reported Income from Continuing Operations for 10 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Income from Continuing Operations rose 8.83% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.9 billion, a 49.6% decrease from a year earlier, with the FY2026 full-year figure at -$845.4 million, down 153.21% from the prior year.
• Income from Continuing Operations was $1.3 billion for Q2 2026 at Takeda Pharmaceutical, down from $1.4 billion in the prior quarter.
• The five-year high for Income from Continuing Operations was $2.8 billion in Q3 2025, with the low at -$3.5 billion in Q4 2025.
• Average Income from Continuing Operations over 5 years is $1.0 billion, with a median of $1.3 billion recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations jumped 297.92% in 2023, then sank 4440.99% in 2024.
• Over 5 years, Income from Continuing Operations stood at $673.6 million in 2022, then plunged by 96.58% to $23.0 million in 2023, then tumbled by 4440.99% to -$998.5 million in 2024, then plunged by 252.45% to -$3.5 billion in 2025, then surged by 137.83% to $1.3 billion in 2026.
• The last three Income from Continuing Operations figures came in at $1.3 billion (Q2 2026), $1.4 billion (Q1 2026), and -$3.5 billion (Q4 2025), per Business Quant data.